UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to _____ Commission File Number: 001-37557 Penumbra, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Exhibit 99.1 Penumbra, Inc. Reports First Quarter 2025 Financial Results ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue increased to $324.1 million for the first quarter of 2025 compared to $278.7 million for the first quarter of 2024, an increase of 16.3%, or 16.9% in constant currency . The United States repre ...

ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024. U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024. Income from operations of $40.4 mil ...

文章核心观点 - 凯斯凯拉律师事务所代表股东对Penumbra公司展开调查，以确定该公司及其高管是否违反证券法或违背对投资者的信托义务 [1][2] 调查相关 - 调查旨在确定Penumbra公司及/或其高管是否因近期公司行动违反证券法或违背对投资者的信托义务 [2] 股东联系方式 - 鼓励Penumbra股东联系凯斯凯拉律师事务所了解调查及自身合法权益和选择，联系电话(484) 229 – 0750，也可点击链接https://kaskelalaw.com/case/penumbra/ [3] 律所信息 - 凯斯凯拉律师事务所仅按或然收费方式代表投资者处理证券欺诈、公司治理及并购诉讼案件，更多信息可访问www.kaskelalaw.com [3] 律所联系方式 - 凯斯凯拉律师事务所联系人包括D. Seamus Kaskela律师(skaskela@kaskelalaw.com)和Adrienne Bell律师(abell@kaskelalaw.com)，地址为18 Campus Blvd., Suite 100, Newtown Square, PA 19073，联系电话(888) 715 – 1740和(484) 229 – 0750 [4]

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Penumbra (PEN) , which belongs to the Zacks Medical - Instruments industry.When looking at the last two reports, this medical device maker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 14.89%, on average, in the last two quarters.For the most recent quarter, Penumbra was expected to post earnings of $0.91 p ...

文章核心观点 - Penumbra公司血栓切除业务蓬勃发展，产品组合扩张将推动未来增长，但不利外汇和激烈竞争或带来运营风险 [1] 公司表现 - 过去一年公司股价上涨19.8%，行业下跌18.4%，标普500指数下跌1.9% [2] - 公司市值101.5亿美元，过去四个季度三次盈利超预期，一次未达预期，平均惊喜率10.42% [2] 发展顺风因素 强大的产品组合扩张 - 2025年1月推出Element血管通路系统，同年还推出Lightning Bolt 12和带TraX的Lightning Bolt 6x，旨在加强动静脉血栓管理 [3] - 2024年9月中旬Lightning Flash 2.0和Lightning Bolt 7获得CE认证，正将技术引入欧洲市场 [3] - 公司计划专注于Flash和Bolt创新，预计CAVT产品组合将推动深静脉血栓、肺栓塞和动脉领域的市场份额和增长 [4] - 截至2025年2月，Thunderbolt抽吸导管正在进行治疗急性缺血性中风的THUNDER IDE临床研究 [4] 血栓切除业务强劲增长 - 公司血栓切除业务增长强劲，得益于美国血管血栓切除产品和CAVT产品线销售快速增长 [5] - 公司正与欧洲、亚太和拉丁美洲的监管和报销机构合作，将整个CAVT产品组合推向国际患者 [5] - 2024年第四季度，美国血栓切除业务同比增长27.3%，美国VTE业务收入同比增长41% [6] 发展逆风因素 外汇影响销售 - 公司大部分销售和成本受外汇汇率变化影响，运营使用多种外币，汇率变化会影响销售、成本和净利润 [7] 竞争激烈 - 公司处于竞争激烈的医疗设备行业，大公司资源更多，可在产品开发和营销上投入更多，还需与小公司竞争 [9] 股票估计趋势 - 过去30天，Zacks对公司2025年盈利共识估计下降0.5%至3.64美元 [10] - Zacks对公司2025年营收共识估计为13.5亿美元，较上年增长13.1% [10] 其他推荐股票 菲布罗动物健康（PAHC） - 预计2025财年盈利增长率62.2%，高于行业的17.2% [11] - 过去四个季度盈利均超Zacks共识估计，平均惊喜率27.06% [11] - 过去一年股价上涨73.5%，高于行业的9.5%，目前Zacks排名为1（强力买入） [11][12] 波士顿科学（BSX） - 目前Zacks排名为2（买入），盈利收益率2.7%，高于行业的1.5% [12] - 过去一年股价上涨47.1%，高于行业的9.5%，过去四个季度盈利均超预期，平均惊喜率8.25% [12] 卡地纳健康（CAH） - 目前Zacks排名为2，预计长期盈利增长率10.7%，高于行业的9.5% [13] - 过去一年股价上涨17.5%，行业下跌3.2%，过去四个季度盈利均超预期，平均惊喜率9.64% [13]

文章核心观点 - Purcell & Lefkowitz LLP代表Penumbra公司股东对其展开调查，以确定董事是否在近期公司行动中违反信托责任 [1] 公司相关 - Purcell & Lefkowitz LLP是一家专门代表全国范围内受证券欺诈、信托责任违约和其他公司不当行为侵害的股东的律师事务所 [2] - Penumbra公司股东若想免费获取自身权利和选择的更多信息，可访问https://pjlfirm.com/penumbra-inc/ ，也可通过邮箱[email protected]或电话212 - 725 - 1000联系Robert H. Lefkowitz, Esq.，律所律师将免费无义务与股东沟通案件 [1]

ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the web ...

ALAMEDA, Calif., April 2, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced seven significant computer assisted vacuum thrombectomy (CAVT™) data presentations during the 2025 Society of Interventional Radiology (SIR) Annual Scientific Meeting. The data showed that CAVT as a frontline therapy for blood clots not only improved clinical and functional outcomes but can also help reduce overall healthcare costs.  Seven New Data Sets Demonstrate Penumbra’s Co ...

Penumbra (PEN) is gaining traction in the U.S. and international markets on strong customer uptake of its Lightning Bolt and Flash lines. Yet, unfavorable currency movements and rising expenses are major dampeners for Penumbra. The stock carries a Zacks Rank #3 (Hold).Factors Driving PEN SharesPenumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States as well as its CAVT line ...